Skip to main content
. Author manuscript; available in PMC: 2022 Jun 10.
Published in final edited form as: EC Microbiol. 2022 Mar 8;18(4):1–12.

Figure 1:

Figure 1:

Brilacidin inhibits infection by replication-competent SARS-CoV-2 viruses. (A) The structure of brilacidin tetrahydrochloride. (B) Replication-competent SARS-CoV-2 viruses expressing mNeonGreen were incubated (MOI of 5) with brilacidin at different concentrations at 37°C for 1h and then added to Vero E6 cells for 2h. Infected cells were then cultured in FluoroBrite medium with 10% FBS in the presence of the inhibitor for 24 or 48h. (C) Vero E6 cells were exposed to replication-competent SARS-CoV-2 viruses expressing mNeonGreen for 2h. Infected cells were washed with PBS and then treated with brilacidin at different concentrations for 24h. Fluorescence from productive viral infections was measured using a Biotek Cytation 5. Differences between brilacidin-treated viruses and non-treated control viruses were calculated by one-way ANOVA; *p < 0.05. Data represent mean ± SD of three replicates.